![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, February 22, 2020 8:40:09 AM
https://nwbio.com/wp-content/uploads/Boston-Presentation-v0.2.pdf
" (Near) Future Plans in Brain Cancer
•Unblinding and analyzing the Phase III data
•Combination trials of DCVax®-L with checkpoint inhibitor molecules
•Intratumoral injection of DCVax®-Direct (a related product) in brain metastases
•Intratumoral injection of DCVax®-Direct in diffuse intrinsic pontine glioma (DIPG)"
And now remember the news of annual shareholder meeting of 18 Feb 2020, to be held on 18 April 2020:
https://finance.yahoo.com/news/nw-bio-announces-annual-shareholders-141500981.html
Then it's pretty much reasonable that we are currently in the process of unblinding and analysis of TLD.
Anytime I hears someone says buying nwbo shares is like buying a lottery ticket, I feel it's an insult to the collective DD of so many true longs who have invested heavily based on own profound knowledge of cancer vaccine immunotherapy applied for GBM, the known blinded data and decades of stagnation deprived of any concrete progress in treating GBM patients; we have a thick and long tail of patients indicative from the blinded data, and a very significant portion of patients who live longer than the known prognostic factors can explain ...
Of course, nobody is certain the DCVax-L P3 trial will be approved successful and the vaccine will be approved by FDA, etc., but the odds of that kind of success is very high based on what we have known.
I hope what is developing in the near future will finalize my decision whether going to washington DC or not, and then see you all in the meeting!
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM